Radius Health has been granted a patent for a method of treating Prader-Willi syndrome using a stable cannabinoid pharmaceutical formulation containing cannabidiol. The oral formulation includes specific concentrations of ingredients for effective treatment. GlobalData’s report on Radius Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Radius Health Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Radius Health, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Radius Health's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for treating prader-willi syndrome with cannabidiol formulation

Source: United States Patent and Trademark Office (USPTO). Credit: Radius Health Inc

A recently granted patent (Publication Number: US11911361B2) discloses a method for treating Prader-Willi syndrome using an oral pharmaceutical formulation. The formulation includes cannabidiol, caprylic/capric triglyceride, alpha tocopherol, a sweetener, and a flavoring agent. The method aims to address symptoms of Prader-Willi syndrome, particularly hyperphagia, in pediatric subjects. The dosage of cannabidiol is specified at about 40 milligrams per kilogram of body weight per day, with the cannabidiol being of high purity, greater than 98%, and potentially synthetic.

The patent outlines specific compositions of the oral pharmaceutical formulation, ranging from 8% to 32% w/w of cannabidiol, along with varying concentrations of caprylic/capric triglyceride, alpha tocopherol, sweetener, and flavoring agent. The formulations provide flexibility in the percentage composition of the key ingredients, allowing for customization based on individual needs and responses. By targeting hyperphagia, a common symptom of Prader-Willi syndrome characterized by excessive hunger, the method offers a potential treatment option for pediatric patients. The patent's detailed specifications provide a clear framework for administering the formulation effectively, highlighting the importance of precise dosages and ingredient purity in treating the syndrome.

To know more about GlobalData’s detailed insights on Radius Health, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies